T
Tim Eisen
Researcher at University of Cambridge
Publications - 182
Citations - 16540
Tim Eisen is an academic researcher from University of Cambridge. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 49, co-authored 177 publications receiving 15253 citations. Previous affiliations of Tim Eisen include Institute of Cancer Research & University of Chicago.
Papers
More filters
Journal ArticleDOI
Sorafenib in advanced clear-cell renal-cell carcinoma.
Bernard Escudier,Tim Eisen,Walter M. Stadler,Cezary Szczylik,Stéphane Oudard,Michael Siebels,Sylvie Negrier,Christine Chevreau,Ewa Solska,Apurva A. Desai,Frederic Rolland,Tomasz Demkow,Thomas E. Hutson,Martin Gore,Scott Freeman,Brian Schwartz,M. Shan,Ronit Simantov,Ronald M. Bukowski +18 more
TL;DR: As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is associated with increased toxic effects.
Journal ArticleDOI
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier,Tim Eisen,Walter M. Stadler,Cezary Szczylik,Stéphane Oudard,Michael Staehler,Sylvie Negrier,Christine Chevreau,Apurva A. Desai,Frederic Rolland,Tomasz Demkow,Thomas E. Hutson,Martin Gore,Sibyl Anderson,Gloria Hofilena,M. Shan,Carol Peña,Chetan Lathia,Ronald M. Bukowski +18 more
TL;DR: Although an OS benefit was not seen on a primary intent-to-treat analysis, results of a secondary OS analysis censoring placebo patients demonstrated a survival advantage for those receiving sorafenib, suggesting an important cross-over effect.
Journal ArticleDOI
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
Mark J. Ratain,Tim Eisen,Walter M. Stadler,Keith T. Flaherty,Stan B. Kaye,Gary L. Rosner,Martin Gore,Apurva A. Desai,Amita Patnaik,Henry Q. Xiong,Eric K. Rowinsky,James L. Abbruzzese,Chenghua Xia,Ronit Simantov,Brian Schwartz,Peter O'Dwyer +15 more
TL;DR: Sorafenib has significant disease-stabilizing activity in metastatic renal cell carcinoma and is tolerable with chronic daily therapy.
Journal ArticleDOI
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
Tim Eisen,Tanya Ahmad,Keith T. Flaherty,Martin Gore,Stan B. Kaye,Richard Marais,I Gibbens,S Hackett,M. G. James,Lynn M. Schuchter,Katherine L. Nathanson,Chenghua Xia,Ronit Simantov,Brian Schwartz,M Poulin-Costello,Peter O'Dwyer,Mark J. Ratain +16 more
TL;DR: Sorafenib is well tolerated but has little or no antitumour activity in advanced melanoma patients as a single agent at the dose evaluated (400 mg b.i.d.) and there was no relationship between V600E BRAF status and disease stability.
Journal ArticleDOI
VHL, the story of a tumour suppressor gene
TL;DR: It is timely to review progress from its initial description to current knowledge of VHL biology, as well as future prospects for novel medical treatments for VHL disease and ccRCC.